Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Post-Brexit UK Could Be ‘Back Of The Queue’ For Drug Access, Warns MHRA Chair

Executive Summary

Professor Sir Michael Rawlins, chair of the MHRA, has told a UK committee of his concerns over Brexit, including possible delays in access to new drugs, a decline in revenues for regulatory work on behalf of the EU, and the possibility that some firms’ HQs might follow the European Medicines Agency if it relocates to another European country.


Related Content

Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
UK Industry Pleased With Brexit Committee's Focus On Regulation





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts